By
Dr Auwal Ahmad
Department of Haematology
Moderated by
Dr J. M. El Bashir
1/29/2024
Biochemical Investigation and
Management of Sickle Cell
Nephropathy
1
Outline
 Introduction
 Epidemiology
 Pathophysiology
 Clinical features
 Investigations
 Management
 Conclusion
 References
1/29/2024
2
Introduction
 Sickle cell disorder is an autosomal recessive
disorder caused by a point mutation leading to
replacement of glutamic acid for valine at the
sixth amino acid of beta-globin
 In this disorder, RBCs become sickled when
exposed to conditions of low oxygen tension
 Polymerization of deoxygenated haemoglobin
 Red cell distortion, haemolytic anaemia, micro-
vascular obstruction, and ischaemic tissue
damage
1/29/2024
3
Introduction
 In Sickle cell disease (SCD), there is inheritance
of HbS
• Homozygous state (HbSS) referred to as Sickle cell
anaemia
• Heterozygous state
 Normal: eg HbA (HbAS) is the sickle cell trait
 Compound: HbC, HbD and HbE refered to as SCD
 The hallmark of SCD is haemolysis, widespread
vaso-occlusion, ischaemia reperfusion injury and
subsequent multi-organ damage
1/29/2024
4
Introduction
 Sickle cell disorders may lead to a variety of
alterations in renal morphology and function leading
to clinically significant abnormalities collectively
known as Sickle cell nephropathy. These are:
• Proteinuria
• Hyposthenuria
• Renal Papillary necrosis and Haematuria
• Sickle cell glomerulopathy
• Renal Tubular Disorders
 Significant renal involvement occurs more frequently
in SCD than in sickle cell trait
1/29/2024
5
Epidemiology
 SCD is prevalent in malaria-endemic regions due
to protective carrier state
 Increasing occurrence in non-endemic regions
due to population movements
 About 24% in adult Nigerians and about 8% in
African-Americans ----WHO 59th WHA
 Renal complications as significant cause of
morbidity and mortality
 Incidence of renal failure rising with improved
patient survival -------Aeddula NR et al island
2022
1/29/2024
6
Epidemiology
 Renal involvement occurs in ~60% of patients
with SCD only 4-12% will develop end-stage renal
disease (ESRD) (Powers et al 2005)
 SCN accounts for <1% of all new cases of ESRD
( US)
 Proteinuria is common in SCD occurring in about
30% of patients
 16-18% of mortality in SCD is ascribed to kidney
disease
1/29/2024
7
Epidemiology
1/29/2024
8
S/N Location Prevalenc
e
comment Reference
1 Zaria 66.3%
1.4%
2.5%
CKD in Addult
CKD4
microalbimunuria
R. Yusuf et al 2017
2 Maiduguri 38.9%
26..8%
3.5%
CKD
Hyperfiltration
ESRD
A.A., Bukar et al
2019
3 Oweri 3.4%
6.7%
Proteinuria
Haematuria
U. Nnagi et al 2020
4 Nigeria 26%
32.8%
Microalbimunuria
Increased eGFR
I. Ocheke et al
2019
Epidemiology---Risk Factors
 risk factors associated with progression of
chronic kidney disease (CKD) in SCN
 Genetic variants of MYH9 and APOL1
 Infection with parvovirus B19
 Recurrent Acute chest syndrome
 Vaso occlusive episodes
 Nephrotic range proteinuria
 Underlying hypertension
 Severe anemia
 Genetic modifiers may affect renal dysfunction
1/29/2024
9
Risk Factors
 Genetic Modifiers and Renal Dysfunction
 Renal dysfunction more severe in HbSS and
HbSb0 thalassaemia genotypes (SCA)
 Lower HbF levels correlate with renal failure risk
and vaso-occlusive complications
 Co-inheritance of α-thalassaemia reduces HbS
concentration, red cell volume, and haemolysis
1/29/2024
10
Pathophysiology
 Normal Kidney Physiology and SCN
 Kidneys filter plasma at ~100 ml/min/1.73 m² rate,
receive 25% cardiac output
 SCD phenotype variation but similar blood flow to
kidneys
 Renovascular pathology targeted by multi-organ
vasculopathy linked to chronic nitric oxide (NO)
depletion from intravascular haemolysis
 Activation of hypoxia inducible factor 1a (HIF1a) and
local Endothelin-1 release contribute to chronic
medullary hypoxia
 NO deficiency pivotal in pulmonary hypertension and
progression of SCN 1/29/2024
11
Pathophysiology
1/29/2024
12
Pathophysiology
1/29/2024
13
Renal manifestations of sickle cell
disease
1/29/2024
14
 Alterations in renal haemodynamics
 Increased renal blood flow rate
 Increased renal plasma flow rate
 Increased glomerular filtration rate
 Decreased renal vascular resistance
 Decreased filtration fraction
 Decreased medullary perfusion
 Renal and glomerular enlargement
 Hyperfunction of the proximal tubule
 Increased reabsorption of phosphate and β2-
microglobulin
 Increased secretion of creatinine and uric acid
Renal manifestations of sickle cell
disease
1/29/2024
15
 Glomerulopathies
 Focal segmental glomerulosclerosis
 Membranoproliferative glomerulonephritis
 Thrombotic microangiopathy
 Tubular deposits of iron
 Chronic tubulointerstitial disease
 Impaired function of the distal nephron
 Decreased urinary concentrating ability
 Partial distal renal tubular acidosis
 Impaired renal potassium excretion
Renal manifestations of sickle cell
disease
1/29/2024
16
 Increased susceptibility to acute kidney injury
 Chronic kidney disease and its progression to end-
stage renal disease
 Haematuria
 Renal papillary necrosis
 Increased susceptibility to urinary tract infections
 Renal medullary carcinoma
Pathophysiology
1/29/2024
17
Clinical Features
1/29/2024
18
 Asymptomatic
 Diminished concentrating ability (hyposthenuria)
 Present with thirst, nocturia and polyuria
 Dehydration leading to acute vaso-occlusive crises
 Sickling in the vasa rectae interferes with countercurrent
exchange in the inner medulla
 Hematuria – Painless microscopic or gross hematuria
– Due to papillary infarcts, microthrombosis in
peritubular capillaries, infections, or transfusion
reaction
 Renal infarction & papillary necrosis
 Nausea, vomiting, flank or abdominal pain, fever
 Hypertension (renin-mediated) Renal tubular acidosis –
Diminished medullary blood flow and hypoxia ->
Impaired distal H and K secretion -> incomplete dRTA
Clinical Features
1/29/2024
19
 Abnormal proximal tubular function (Supranormal) –
Hyperphosphatemia <- increased phosphate
reabsorption – Elevated creatinine clearance (due to
enhanced creatinine secretion) in relation to the true
glomerular filtration rate (GFR)
 Acute kidney injury
 Impaired concentrating ability -> dehydration -> prerenal
AKI
 Intrinsic renal causes of AKI include rhabdomyolysis,
sepsis, drug nephrotoxicity, renal vein thrombosis, and
hepatorenal syndrome (hemosiderosis-induced hepatic
failure)
 Postrenal causes include urinary tract obstruction e.g.
secondary to blood clots
Clinical Features
1/29/2024
20
 Urinary tract infection – Impaired immunity
(autosplenectomy) -> opsonic antibody deficiency
- > encapsulated organisms)
 Can precipitate a sickle cell crisis
 Nephrotic Syndrome
 Rare -> poor prognosis
 MPGN -> FSGS – Direct effect of sickled RBCs
 Secondary MPGN <- hepatitis C infection (multiple
blood transfusions)
Clinical Features
1/29/2024
21
 CKD
 Symptoms develop slowly and aren't specific to the disease
 Asymptomatic, nausea and vomiting, fatigue, loss of appetite,
malaise, muscle cramps, swellings, dry and itchy skin,
breathlessness, insomnia, polyuria or oliguria,
 high blood pressure
 Renal medullary carcinoma
 Rare; ~ 1 in 20,000 • Almost exclusive with sickle cell trait
(less commonly, sickle cell disease)
 Present with gross hematuria, UTI, flank pain, an abdominal
mass, and/or weight loss
 Diagnosis via imaging (CT scan)
 Highly aggressive malignancy
 Metastasis at time of diagnosis
 Poor prognosis
Investigations
1/29/2024
22
 Biochemical and non biochemical
 Biochemical
 Urinalysis with microscopy using spot urine, morning
urine or 24hr urine collection
 Assess proteinuria/albuminuria
 Renal function panel
 Electrolytes, urea and critinine
 eGFR calculation using
 Inulin eGFR
 Creatinine eGFR
 Lipid profile
 Other markers of renal function
Investigations --- urinalysis
1/29/2024
23
 Physical examination describes the volume, color,
clarity, odor, and specific gravity.
 Chemical examination identifies pH, red blood
cells, white blood cells, proteins, glucose,
urobilinogen, bilirubin, ketone bodies, leukocyte
esterase, and nitrites.
 Microscopic examination encompasses the
detection of casts, cells, crystals, and
microorganisms.
 Proteinuria, haematuria, USG, PH
Investigations --- urinalysis
1/29/2024
24
 Proteinuria can my categorized as a glomerular
pattern, a tubular pattern, and an overflow pattern
 Albuminuria
 According to the Kidney Disease Improving
Global Outcomes (KDIGO) guidelines,
albuminuria can be classified into three stages
 uACR/uPCR
Investigations --- urinalysis
1/29/2024
25
Albuminuria
stage
Description ACR (mg/mmol
creatinine)
A1 Normal to mildly
increased
<3 Reference
ranges: women
<3.5 mg/mmol;
men <2.5
mg/mmol
A2 Moderately
increased
3-30 Commonly
referred to as
‘’micro-
albuminuria’’
A3
Example ;
G3bA2 denotes
GFR 30-
44mL/min & ACR
Severely
increased
>30 Detectable using
conventional
dipsticks
Investigations --- urinalysis
1/29/2024
26
 Haematuria
Dipstick test for blood detects primarily the
peroxidase activity of erythrocytes, but
myoglobin and hemoglobin can also catalyze
this reaction. Thus, a positive test result
indicates hematuria, myoglobinuria, or
hemoglobinuria.
Electrolytes, urea and critinine
1/29/2024
27
 INCREASED
 Potassium
 Urea
 Creatinine
 Hydrogen ion
 Phosphate
 Magnesium
 DECREASED
 Sodium
 Bicarbonate
 Calcium
eGFR
1/29/2024
28
1/29/2024
29
CKD Stage GFR (mL/min/1.73m2) Description
1 >90 Normal or increased
GFR with other
evidence of kidney
damage
2 60-89 Mild reduction in GFR,
with other evidence of
kidney damage
3 30-59
3a 45-59
3b 30-44
Moderately reduced
GFR, with or without
evidence of kidney
injury
4 15-29 Severely reduced GFR
5 <15 End-stage or
approaching end-stage
kidney failure
5D <15 On dialysis
Investigations
1/29/2024
30
 Can be classified base on the renal structure affected by
the pathological process
 Markers of glomerular damage
 Transferrin
 igG
 Ceruloplasmin
 Type IV collagen
 Laminin
 Glycosaminoglycans
 Lipocalin type prostaglandin D synthase
 Fibronectin
 Podocalyxin
 VEGF
 Cystatin C
 nephrin
Investigations
1/29/2024
31
 Tubular damage markers
 Neutrophils gelatinase associated lipocalin(NGAL)
 Alpha-1-microglobulin
 Kidney injury molecule-1(KIM-1)
 N-acetyl-beta-D-glucosaminidase
 Angiotensinogen
 Uromodulin
 Liver type fatty-acid binding protein (L-FABP)
 Heart-type fatty acid binding protein (H-FABP)
Investigations
1/29/2024
32
 Non biochemical
 Hb electrophoresis
 Full blood count and Differential
 Viral serologies
 Renal ultrasound – Early - > large, variable
echogenicity – Shrink with CKD – Papillary necrosis
• Increased echogenicity of the inner medulla • In
more advanced cases, a filling defect in the area of
the medullary tip can be seen
Management
1/29/2024
33
 This can be divided into management of SCD and the
management of nephropathy
 SCD complications such as frequent crisis and
anaemia are controlled by;
- Blood transfusion
- Hydroxyurea (HU)
 HU may reduce proteinuria and hyperfiltration, better
urine concentrating ability and less renal enlargement
Management
1/29/2024
34
 Patients with proteinuria (uACR>50mg/mmol)
should be treated
 Either with an angiotensin converting enzyme
inhibitor (ACEI) or an angiotensin receptor
blocker (ARB) starting at a low dose
 When taken at night these drugs also reduce
nocturia
 Treatment of anaemia; the target Hb level should
be no greater than 10-10.5g/dL
 A rise in haematocrit of greater than 1-2% per
week should be avoided
Management
1/29/2024
35
 Erthrocyte-stimulating agents (ESA) such as
erythropoietin can improve Hb level and
reduce transfusion requirement in some
patients
 Though blood transfusion provides higher
amount of HbA compared with patients own
blood
 Addition of ESA may allow administration of
higher doses of HU and improve foetal Hb
Management
1/29/2024
36
 Haematuria in SCN is typically self-limiting
 Treatment consists of bed rest and
maintenance of high urine flow rate
 In cases of massive haematuria include;
 Urine alkalinization to minimize Hb
precipitation, loop diuretics to prevent micro-
tubular obstruction and blood transfusion to
reduce HbS and sickling
Management
1/29/2024
37
 Refractory cases may require high doses of
oral urea which has an inhibitory effect on
gelation of deoxygenated sickled Hb
 Treatment with vasopressin or epsilon amino
caproic acid to promote clotting
 Angiographic embolization of renal vessels or
balloon tamponade may be considered
Management
1/29/2024
38
 The relatively small size of the SCD-ESRD
population has limited the development of
optimal management strategies
 Renal replacement therapy is considered in
ESRD
 The therapeutic options include;
1. Haemodialysis
2. peritoneal dialysis
3. Kidney transplantation
Conclusion
1/29/2024
39
SCD
may lead to a variety of alterations in renal
morphology and function, some of which
produce clinically significant abnormalities that
may be present from the first year of life. The
lack of diagnostic test capable of detecting
those at risk, and detecting onset of
symptoms remains a barrier to instituting
therapy. The absence of therapeutic strategy
compounds the management of SCN
1/29/2024
40
 Thank you all for listening
References
1/29/2024
41
 Aeddula NR, Bardhan M, Baradhi KM. Sickle Cell Nephropathy. Ncbi.
2020. Available from https://www.ncbi.nlm.nih.gov . [Date accessed July,
2020]
 Alpers CE, Chang A. The Kidney. Robbins and Cotran Pathologic Basis
of Diseases. Saunders Elsevier. Ninth Edition. Chapter 20. Pg 911-919
 Inusa BPD, Mariachiara L, Giovanni P, Ataga KI. Sickle Cell
Nephropathy: Current Understanding of the Presentation, Diagnostic
and Therapeutic Challenges. Intechopen. 2018. Available from
https://www.intechopen.com .[Date accessed July, 2020]
 Kumar V, Abbas AK, Aster JC. Red Blood Cell and Bleeding Disorders.
Robbins and Cotran Pathologic Basis of Diseases. Saunders Elsevier.
Ninth Edition. Chapter 14. Pg 635
 Marshal WJ, Lapsley M, Day A. The Kidneys. Clinical Chemistry.
Elsevier. Eight Edition. Pg 86
 Mohan Harsh. The Kidney and Lower Urinary Tract. Textbook of
Pathology. Jaypee. Seventh Edition. Chapter 20. Pg 636-638
 Pham PT. Renal Manifestations of Sickle Cell Disease. Medscape.
2019. Available from http://emedicine.medscape.com. [Date accessed
July, 2020]
References
1/29/2024
42
 Bukar, A. A., Sulaiman, M. M., Ladu, A. I., Abba, A. M., Ahmed, M. K., Marama, G. T., & Abjah, U. M. (2019).
Chronic kidney disease amongst sickle cell anaemia patients at the University of Maiduguri Teaching
Hospital, Northeastern Nigeria: A study of prevalence and risk factors. Mediterranean Journal of Hematology
and Infectious Diseases, 11(1).

 Yusuf, R., Hassan, A., Ibrahim, I. N., Babadoko, A. A., & Ibinaiye, P. O. (2017). Assessment of kidney
function in sickle cell anemia patients in Zaria, Nigeria. Sahel Medical Journal, 20(1), 21.

 Nnaji, U. M., Ogoke, C. C., Okafor, H. U., & Achigbu, K. I. (2020). Sickle cell nephropathy and associated
factors among asymptomatic children with sickle cell anaemia. International Journal of Pediatrics, 2020.

 Ocheke, I. E., Mohamed, S., Okpe, E. S., Bode-Thomas, F., & McCullouch, M. I. (2019). Microalbuminuria
risks and glomerular filtration in children with sickle cell anaemia in Nigeria. Italian journal of pediatrics, 45, 1-
6.

 BRAIMOH, R. W., Ale, O. K., & Adewunmi, J. A. (2017). Evaluation of urinary tract infection and nephropathy
in adult Nigerians with sickle cell anaemia. Tropical Journal of Nephrology, 12(2), 23-30.

 WHO FIFTY-NINTH WORLD HEALTH ASSEMBLY A59/9 Provisional agenda item 11.4 24 April 2006

 Aeddula NR, Bardhan M, Baradhi KM. Sickle Cell Nephropathy. [Updated 2022 Sep 12]. In: StatPearls
[Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from:
https://www.ncbi.nlm.nih.gov/books/NBK526017/

More Related Content

PPTX
biochemical analysis of acute kidney injury and chronic kidney disease
PPTX
Acute kidney injury in children.pptx
DOCX
Chronic renal failure
PDF
Acute and Chronic Renal Failure.........
PPTX
26 ckd by mersha
PPTX
uremia, treatment, symptoms , 12222.pptx
PPTX
Chronic Renal Failure.pptx
PDF
Chronic kidney disease (CKD) - AMBOSS.pdf
biochemical analysis of acute kidney injury and chronic kidney disease
Acute kidney injury in children.pptx
Chronic renal failure
Acute and Chronic Renal Failure.........
26 ckd by mersha
uremia, treatment, symptoms , 12222.pptx
Chronic Renal Failure.pptx
Chronic kidney disease (CKD) - AMBOSS.pdf

Similar to Biochemical investigations and management of sickle cell nephropathy.pptx (20)

PPTX
Nephrorounds3 2015final-150907110921-lva1-app6892
PPTX
A rare Case presentation (Dr. Mahallawy).pptx
PPTX
CGN Presentation by Rebira Workineh.pptx
PPTX
Chronic Kidney Disease Management and care
DOCX
Uremia and Uremic Syndrome
PPTX
ACUTE KIDNEY INJURY (PATHOPHYSIOLOGY, DIAGNOSIS,.pptx
PPT
Chronic renal failure(2010505)
PPT
Chronic renal failure(2010505)
PPTX
Approach to a child with acute kidney injury
PPTX
Acid Base Disorders educational power point.pptx
PPTX
Chronic Glomerulonephritis.pptx
PPTX
Chronic kidney disease(ckd)
PDF
MCDP_Renal.pdf
PDF
akifinal-140719124910-phpapp01-1.pdf
PPTX
Acute Kidney Injury
PPTX
CKD-kalemba.pptx
PPTX
Chronic Renal Failure (End Stage Renal Failure)
PPTX
Chronic kidney disease
PPTX
ACUTE KIDNEY INJURY / ACUTE RENAL FAILURE
PPTX
Sickle cell nephropathy in Pediatrics.pptx
Nephrorounds3 2015final-150907110921-lva1-app6892
A rare Case presentation (Dr. Mahallawy).pptx
CGN Presentation by Rebira Workineh.pptx
Chronic Kidney Disease Management and care
Uremia and Uremic Syndrome
ACUTE KIDNEY INJURY (PATHOPHYSIOLOGY, DIAGNOSIS,.pptx
Chronic renal failure(2010505)
Chronic renal failure(2010505)
Approach to a child with acute kidney injury
Acid Base Disorders educational power point.pptx
Chronic Glomerulonephritis.pptx
Chronic kidney disease(ckd)
MCDP_Renal.pdf
akifinal-140719124910-phpapp01-1.pdf
Acute Kidney Injury
CKD-kalemba.pptx
Chronic Renal Failure (End Stage Renal Failure)
Chronic kidney disease
ACUTE KIDNEY INJURY / ACUTE RENAL FAILURE
Sickle cell nephropathy in Pediatrics.pptx
Ad

Recently uploaded (20)

PPTX
Surgical anatomy, physiology and procedures of esophagus.pptx
PPTX
ANTI BIOTICS. SULPHONAMIDES,QUINOLONES.pptx
PPTX
GAIT IN HUMAN AMD PATHOLOGICAL GAIT ...............
PPTX
Geriatrics_(0).pptxxvvbbbbbbbnnnnnnnnnnk
PPTX
Approach to Abdominal trauma Gemme(COMMENT).pptx
PDF
Tackling Intensified Climatic Civil and Meteorological Aviation Weather Chall...
PPT
BONE-TYPES,CLASSIFICATION,HISTOLOGY,FRACTURE,
PPTX
ACUTE PANCREATITIS combined.pptx.pptx in kids
PDF
The Role of Medicinal Plants in Alleviating Symptoms of Diabetes-Related Com...
PPTX
المحاضرة الثالثة Urosurgery (Inflammation).pptx
PDF
FMCG-October-2021........................
PDF
Nematodes - by Sanjan PV 20-52.pdf based on all aspects
PDF
Integrating Traditional Medicine with Modern Engineering Solutions (www.kiu....
PDF
Cranial nerve palsies (I-XII) - AMBOSS.pdf
PPTX
ENT-DISORDERS ( ent for nursing ). (1).p
PPTX
IMMUNITY ... and basic concept mds 1st year
PDF
NCCN CANCER TESTICULAR 2024 ...............................
PPTX
Acute Abdomen and its management updates.pptx
PPT
ANTI-HYPERTENSIVE PHARMACOLOGY Department.ppt
PPTX
Bronchial Asthma2025 GINA Guideline.pptx
Surgical anatomy, physiology and procedures of esophagus.pptx
ANTI BIOTICS. SULPHONAMIDES,QUINOLONES.pptx
GAIT IN HUMAN AMD PATHOLOGICAL GAIT ...............
Geriatrics_(0).pptxxvvbbbbbbbnnnnnnnnnnk
Approach to Abdominal trauma Gemme(COMMENT).pptx
Tackling Intensified Climatic Civil and Meteorological Aviation Weather Chall...
BONE-TYPES,CLASSIFICATION,HISTOLOGY,FRACTURE,
ACUTE PANCREATITIS combined.pptx.pptx in kids
The Role of Medicinal Plants in Alleviating Symptoms of Diabetes-Related Com...
المحاضرة الثالثة Urosurgery (Inflammation).pptx
FMCG-October-2021........................
Nematodes - by Sanjan PV 20-52.pdf based on all aspects
Integrating Traditional Medicine with Modern Engineering Solutions (www.kiu....
Cranial nerve palsies (I-XII) - AMBOSS.pdf
ENT-DISORDERS ( ent for nursing ). (1).p
IMMUNITY ... and basic concept mds 1st year
NCCN CANCER TESTICULAR 2024 ...............................
Acute Abdomen and its management updates.pptx
ANTI-HYPERTENSIVE PHARMACOLOGY Department.ppt
Bronchial Asthma2025 GINA Guideline.pptx
Ad

Biochemical investigations and management of sickle cell nephropathy.pptx

  • 1. By Dr Auwal Ahmad Department of Haematology Moderated by Dr J. M. El Bashir 1/29/2024 Biochemical Investigation and Management of Sickle Cell Nephropathy 1
  • 2. Outline  Introduction  Epidemiology  Pathophysiology  Clinical features  Investigations  Management  Conclusion  References 1/29/2024 2
  • 3. Introduction  Sickle cell disorder is an autosomal recessive disorder caused by a point mutation leading to replacement of glutamic acid for valine at the sixth amino acid of beta-globin  In this disorder, RBCs become sickled when exposed to conditions of low oxygen tension  Polymerization of deoxygenated haemoglobin  Red cell distortion, haemolytic anaemia, micro- vascular obstruction, and ischaemic tissue damage 1/29/2024 3
  • 4. Introduction  In Sickle cell disease (SCD), there is inheritance of HbS • Homozygous state (HbSS) referred to as Sickle cell anaemia • Heterozygous state  Normal: eg HbA (HbAS) is the sickle cell trait  Compound: HbC, HbD and HbE refered to as SCD  The hallmark of SCD is haemolysis, widespread vaso-occlusion, ischaemia reperfusion injury and subsequent multi-organ damage 1/29/2024 4
  • 5. Introduction  Sickle cell disorders may lead to a variety of alterations in renal morphology and function leading to clinically significant abnormalities collectively known as Sickle cell nephropathy. These are: • Proteinuria • Hyposthenuria • Renal Papillary necrosis and Haematuria • Sickle cell glomerulopathy • Renal Tubular Disorders  Significant renal involvement occurs more frequently in SCD than in sickle cell trait 1/29/2024 5
  • 6. Epidemiology  SCD is prevalent in malaria-endemic regions due to protective carrier state  Increasing occurrence in non-endemic regions due to population movements  About 24% in adult Nigerians and about 8% in African-Americans ----WHO 59th WHA  Renal complications as significant cause of morbidity and mortality  Incidence of renal failure rising with improved patient survival -------Aeddula NR et al island 2022 1/29/2024 6
  • 7. Epidemiology  Renal involvement occurs in ~60% of patients with SCD only 4-12% will develop end-stage renal disease (ESRD) (Powers et al 2005)  SCN accounts for <1% of all new cases of ESRD ( US)  Proteinuria is common in SCD occurring in about 30% of patients  16-18% of mortality in SCD is ascribed to kidney disease 1/29/2024 7
  • 8. Epidemiology 1/29/2024 8 S/N Location Prevalenc e comment Reference 1 Zaria 66.3% 1.4% 2.5% CKD in Addult CKD4 microalbimunuria R. Yusuf et al 2017 2 Maiduguri 38.9% 26..8% 3.5% CKD Hyperfiltration ESRD A.A., Bukar et al 2019 3 Oweri 3.4% 6.7% Proteinuria Haematuria U. Nnagi et al 2020 4 Nigeria 26% 32.8% Microalbimunuria Increased eGFR I. Ocheke et al 2019
  • 9. Epidemiology---Risk Factors  risk factors associated with progression of chronic kidney disease (CKD) in SCN  Genetic variants of MYH9 and APOL1  Infection with parvovirus B19  Recurrent Acute chest syndrome  Vaso occlusive episodes  Nephrotic range proteinuria  Underlying hypertension  Severe anemia  Genetic modifiers may affect renal dysfunction 1/29/2024 9
  • 10. Risk Factors  Genetic Modifiers and Renal Dysfunction  Renal dysfunction more severe in HbSS and HbSb0 thalassaemia genotypes (SCA)  Lower HbF levels correlate with renal failure risk and vaso-occlusive complications  Co-inheritance of α-thalassaemia reduces HbS concentration, red cell volume, and haemolysis 1/29/2024 10
  • 11. Pathophysiology  Normal Kidney Physiology and SCN  Kidneys filter plasma at ~100 ml/min/1.73 m² rate, receive 25% cardiac output  SCD phenotype variation but similar blood flow to kidneys  Renovascular pathology targeted by multi-organ vasculopathy linked to chronic nitric oxide (NO) depletion from intravascular haemolysis  Activation of hypoxia inducible factor 1a (HIF1a) and local Endothelin-1 release contribute to chronic medullary hypoxia  NO deficiency pivotal in pulmonary hypertension and progression of SCN 1/29/2024 11
  • 14. Renal manifestations of sickle cell disease 1/29/2024 14  Alterations in renal haemodynamics  Increased renal blood flow rate  Increased renal plasma flow rate  Increased glomerular filtration rate  Decreased renal vascular resistance  Decreased filtration fraction  Decreased medullary perfusion  Renal and glomerular enlargement  Hyperfunction of the proximal tubule  Increased reabsorption of phosphate and β2- microglobulin  Increased secretion of creatinine and uric acid
  • 15. Renal manifestations of sickle cell disease 1/29/2024 15  Glomerulopathies  Focal segmental glomerulosclerosis  Membranoproliferative glomerulonephritis  Thrombotic microangiopathy  Tubular deposits of iron  Chronic tubulointerstitial disease  Impaired function of the distal nephron  Decreased urinary concentrating ability  Partial distal renal tubular acidosis  Impaired renal potassium excretion
  • 16. Renal manifestations of sickle cell disease 1/29/2024 16  Increased susceptibility to acute kidney injury  Chronic kidney disease and its progression to end- stage renal disease  Haematuria  Renal papillary necrosis  Increased susceptibility to urinary tract infections  Renal medullary carcinoma
  • 18. Clinical Features 1/29/2024 18  Asymptomatic  Diminished concentrating ability (hyposthenuria)  Present with thirst, nocturia and polyuria  Dehydration leading to acute vaso-occlusive crises  Sickling in the vasa rectae interferes with countercurrent exchange in the inner medulla  Hematuria – Painless microscopic or gross hematuria – Due to papillary infarcts, microthrombosis in peritubular capillaries, infections, or transfusion reaction  Renal infarction & papillary necrosis  Nausea, vomiting, flank or abdominal pain, fever  Hypertension (renin-mediated) Renal tubular acidosis – Diminished medullary blood flow and hypoxia -> Impaired distal H and K secretion -> incomplete dRTA
  • 19. Clinical Features 1/29/2024 19  Abnormal proximal tubular function (Supranormal) – Hyperphosphatemia <- increased phosphate reabsorption – Elevated creatinine clearance (due to enhanced creatinine secretion) in relation to the true glomerular filtration rate (GFR)  Acute kidney injury  Impaired concentrating ability -> dehydration -> prerenal AKI  Intrinsic renal causes of AKI include rhabdomyolysis, sepsis, drug nephrotoxicity, renal vein thrombosis, and hepatorenal syndrome (hemosiderosis-induced hepatic failure)  Postrenal causes include urinary tract obstruction e.g. secondary to blood clots
  • 20. Clinical Features 1/29/2024 20  Urinary tract infection – Impaired immunity (autosplenectomy) -> opsonic antibody deficiency - > encapsulated organisms)  Can precipitate a sickle cell crisis  Nephrotic Syndrome  Rare -> poor prognosis  MPGN -> FSGS – Direct effect of sickled RBCs  Secondary MPGN <- hepatitis C infection (multiple blood transfusions)
  • 21. Clinical Features 1/29/2024 21  CKD  Symptoms develop slowly and aren't specific to the disease  Asymptomatic, nausea and vomiting, fatigue, loss of appetite, malaise, muscle cramps, swellings, dry and itchy skin, breathlessness, insomnia, polyuria or oliguria,  high blood pressure  Renal medullary carcinoma  Rare; ~ 1 in 20,000 • Almost exclusive with sickle cell trait (less commonly, sickle cell disease)  Present with gross hematuria, UTI, flank pain, an abdominal mass, and/or weight loss  Diagnosis via imaging (CT scan)  Highly aggressive malignancy  Metastasis at time of diagnosis  Poor prognosis
  • 22. Investigations 1/29/2024 22  Biochemical and non biochemical  Biochemical  Urinalysis with microscopy using spot urine, morning urine or 24hr urine collection  Assess proteinuria/albuminuria  Renal function panel  Electrolytes, urea and critinine  eGFR calculation using  Inulin eGFR  Creatinine eGFR  Lipid profile  Other markers of renal function
  • 23. Investigations --- urinalysis 1/29/2024 23  Physical examination describes the volume, color, clarity, odor, and specific gravity.  Chemical examination identifies pH, red blood cells, white blood cells, proteins, glucose, urobilinogen, bilirubin, ketone bodies, leukocyte esterase, and nitrites.  Microscopic examination encompasses the detection of casts, cells, crystals, and microorganisms.  Proteinuria, haematuria, USG, PH
  • 24. Investigations --- urinalysis 1/29/2024 24  Proteinuria can my categorized as a glomerular pattern, a tubular pattern, and an overflow pattern  Albuminuria  According to the Kidney Disease Improving Global Outcomes (KDIGO) guidelines, albuminuria can be classified into three stages  uACR/uPCR
  • 25. Investigations --- urinalysis 1/29/2024 25 Albuminuria stage Description ACR (mg/mmol creatinine) A1 Normal to mildly increased <3 Reference ranges: women <3.5 mg/mmol; men <2.5 mg/mmol A2 Moderately increased 3-30 Commonly referred to as ‘’micro- albuminuria’’ A3 Example ; G3bA2 denotes GFR 30- 44mL/min & ACR Severely increased >30 Detectable using conventional dipsticks
  • 26. Investigations --- urinalysis 1/29/2024 26  Haematuria Dipstick test for blood detects primarily the peroxidase activity of erythrocytes, but myoglobin and hemoglobin can also catalyze this reaction. Thus, a positive test result indicates hematuria, myoglobinuria, or hemoglobinuria.
  • 27. Electrolytes, urea and critinine 1/29/2024 27  INCREASED  Potassium  Urea  Creatinine  Hydrogen ion  Phosphate  Magnesium  DECREASED  Sodium  Bicarbonate  Calcium
  • 29. 1/29/2024 29 CKD Stage GFR (mL/min/1.73m2) Description 1 >90 Normal or increased GFR with other evidence of kidney damage 2 60-89 Mild reduction in GFR, with other evidence of kidney damage 3 30-59 3a 45-59 3b 30-44 Moderately reduced GFR, with or without evidence of kidney injury 4 15-29 Severely reduced GFR 5 <15 End-stage or approaching end-stage kidney failure 5D <15 On dialysis
  • 30. Investigations 1/29/2024 30  Can be classified base on the renal structure affected by the pathological process  Markers of glomerular damage  Transferrin  igG  Ceruloplasmin  Type IV collagen  Laminin  Glycosaminoglycans  Lipocalin type prostaglandin D synthase  Fibronectin  Podocalyxin  VEGF  Cystatin C  nephrin
  • 31. Investigations 1/29/2024 31  Tubular damage markers  Neutrophils gelatinase associated lipocalin(NGAL)  Alpha-1-microglobulin  Kidney injury molecule-1(KIM-1)  N-acetyl-beta-D-glucosaminidase  Angiotensinogen  Uromodulin  Liver type fatty-acid binding protein (L-FABP)  Heart-type fatty acid binding protein (H-FABP)
  • 32. Investigations 1/29/2024 32  Non biochemical  Hb electrophoresis  Full blood count and Differential  Viral serologies  Renal ultrasound – Early - > large, variable echogenicity – Shrink with CKD – Papillary necrosis • Increased echogenicity of the inner medulla • In more advanced cases, a filling defect in the area of the medullary tip can be seen
  • 33. Management 1/29/2024 33  This can be divided into management of SCD and the management of nephropathy  SCD complications such as frequent crisis and anaemia are controlled by; - Blood transfusion - Hydroxyurea (HU)  HU may reduce proteinuria and hyperfiltration, better urine concentrating ability and less renal enlargement
  • 34. Management 1/29/2024 34  Patients with proteinuria (uACR>50mg/mmol) should be treated  Either with an angiotensin converting enzyme inhibitor (ACEI) or an angiotensin receptor blocker (ARB) starting at a low dose  When taken at night these drugs also reduce nocturia  Treatment of anaemia; the target Hb level should be no greater than 10-10.5g/dL  A rise in haematocrit of greater than 1-2% per week should be avoided
  • 35. Management 1/29/2024 35  Erthrocyte-stimulating agents (ESA) such as erythropoietin can improve Hb level and reduce transfusion requirement in some patients  Though blood transfusion provides higher amount of HbA compared with patients own blood  Addition of ESA may allow administration of higher doses of HU and improve foetal Hb
  • 36. Management 1/29/2024 36  Haematuria in SCN is typically self-limiting  Treatment consists of bed rest and maintenance of high urine flow rate  In cases of massive haematuria include;  Urine alkalinization to minimize Hb precipitation, loop diuretics to prevent micro- tubular obstruction and blood transfusion to reduce HbS and sickling
  • 37. Management 1/29/2024 37  Refractory cases may require high doses of oral urea which has an inhibitory effect on gelation of deoxygenated sickled Hb  Treatment with vasopressin or epsilon amino caproic acid to promote clotting  Angiographic embolization of renal vessels or balloon tamponade may be considered
  • 38. Management 1/29/2024 38  The relatively small size of the SCD-ESRD population has limited the development of optimal management strategies  Renal replacement therapy is considered in ESRD  The therapeutic options include; 1. Haemodialysis 2. peritoneal dialysis 3. Kidney transplantation
  • 39. Conclusion 1/29/2024 39 SCD may lead to a variety of alterations in renal morphology and function, some of which produce clinically significant abnormalities that may be present from the first year of life. The lack of diagnostic test capable of detecting those at risk, and detecting onset of symptoms remains a barrier to instituting therapy. The absence of therapeutic strategy compounds the management of SCN
  • 40. 1/29/2024 40  Thank you all for listening
  • 41. References 1/29/2024 41  Aeddula NR, Bardhan M, Baradhi KM. Sickle Cell Nephropathy. Ncbi. 2020. Available from https://www.ncbi.nlm.nih.gov . [Date accessed July, 2020]  Alpers CE, Chang A. The Kidney. Robbins and Cotran Pathologic Basis of Diseases. Saunders Elsevier. Ninth Edition. Chapter 20. Pg 911-919  Inusa BPD, Mariachiara L, Giovanni P, Ataga KI. Sickle Cell Nephropathy: Current Understanding of the Presentation, Diagnostic and Therapeutic Challenges. Intechopen. 2018. Available from https://www.intechopen.com .[Date accessed July, 2020]  Kumar V, Abbas AK, Aster JC. Red Blood Cell and Bleeding Disorders. Robbins and Cotran Pathologic Basis of Diseases. Saunders Elsevier. Ninth Edition. Chapter 14. Pg 635  Marshal WJ, Lapsley M, Day A. The Kidneys. Clinical Chemistry. Elsevier. Eight Edition. Pg 86  Mohan Harsh. The Kidney and Lower Urinary Tract. Textbook of Pathology. Jaypee. Seventh Edition. Chapter 20. Pg 636-638  Pham PT. Renal Manifestations of Sickle Cell Disease. Medscape. 2019. Available from http://emedicine.medscape.com. [Date accessed July, 2020]
  • 42. References 1/29/2024 42  Bukar, A. A., Sulaiman, M. M., Ladu, A. I., Abba, A. M., Ahmed, M. K., Marama, G. T., & Abjah, U. M. (2019). Chronic kidney disease amongst sickle cell anaemia patients at the University of Maiduguri Teaching Hospital, Northeastern Nigeria: A study of prevalence and risk factors. Mediterranean Journal of Hematology and Infectious Diseases, 11(1).   Yusuf, R., Hassan, A., Ibrahim, I. N., Babadoko, A. A., & Ibinaiye, P. O. (2017). Assessment of kidney function in sickle cell anemia patients in Zaria, Nigeria. Sahel Medical Journal, 20(1), 21.   Nnaji, U. M., Ogoke, C. C., Okafor, H. U., & Achigbu, K. I. (2020). Sickle cell nephropathy and associated factors among asymptomatic children with sickle cell anaemia. International Journal of Pediatrics, 2020.   Ocheke, I. E., Mohamed, S., Okpe, E. S., Bode-Thomas, F., & McCullouch, M. I. (2019). Microalbuminuria risks and glomerular filtration in children with sickle cell anaemia in Nigeria. Italian journal of pediatrics, 45, 1- 6.   BRAIMOH, R. W., Ale, O. K., & Adewunmi, J. A. (2017). Evaluation of urinary tract infection and nephropathy in adult Nigerians with sickle cell anaemia. Tropical Journal of Nephrology, 12(2), 23-30.   WHO FIFTY-NINTH WORLD HEALTH ASSEMBLY A59/9 Provisional agenda item 11.4 24 April 2006   Aeddula NR, Bardhan M, Baradhi KM. Sickle Cell Nephropathy. [Updated 2022 Sep 12]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK526017/

Editor's Notes

  • #4: Sickle cell disorder is an autosomal recessive disorder caused by a point mutation causing substitution of thymine for adenine in the sixth codon of the beta globin-chain gene, this causes coding of amino acid valine instead of glutamate in position 6 of the beta-globin chain
  • #5: In Sickle cell disease (SCD), there is inheritance of HbS in the homozygous state or with another abnormal Hb (compound heterozygotes) and clinical manifestations
  • #7: Claire C. Sharpe, Swee L. Thein, Sickle cell nephropathy – a practical approach British Journal of Haematology September 2011
  • #8: Claire C. Sharpe, Swee L. Thein, Sickle cell nephropathy – a practical approach British Journal of Haematology September 2011
  • #10: Onset of CKD gradual, requires ongoing monitoring Microalbuminuria: early manifestation, prevalent in older patients Endstage Renal Disease (ESRD): serious complication in a minority
  • #13: The pathobiology of sickle cell disease. The formation of deoxyHbS leads to RBC sickling and vascular stasis. Stasis induces vascular occlusion, which either leads to infarction or resolves and causes ischaemia–reperfusion and its accompanying processes. Recurrent cycles of ischaemia–reperfusion in microcirculatory beds amplify organ injury (the ‘big bang’ effect) because they induce inflammation and endothelial dysfunction, both regionally and systemically. Endothelial dysfunction promotes adhesion of RBCs and WBCs to the endothelium. This adhesion is critical because it impedes the transit of RBCs through the microcirculation, thereby promoting RBC sickling and vascular stasis. This vascular stasis explains why RBC sickling occurs in the microcirculation, despite the fact that the time required for sickling usually exceeds RBC transit through the microcirculation. Additional pathobiological pathways include haemolysis and increased free plasma haemoglobin. Plasma haemoglobin scavenges NO from the endothelium. Autoxidation and degradation of HbS lead to the release of free haem, which is toxic to the endothelium via its pro-oxidant and proinflammatory properties. Abbreviations: deoxyHbS, deoxygenated HbS; HbS, sickle haemoglobin; NO, nitric oxide; pO2, partial pressure of oxygen; RBC, red blood cell; WBC, white blood cell. Nath, K., Hebbel, R. Sickle cell disease: renal manifestations and mechanisms. Nat Rev Nephrol 11, 161–171 (2015). https://doi.org/10.1038/nrneph.2015.8
  • #14: Salient pathogenetic processes in the development of sickle cell nephropathy. Sickle cell nephropathy largely reflects an underlying functional vasculopathy. This vasculopathy leads to a perfusion paradox, wherein medullary hypoperfusion occurs in conjunction with kidney and/or cortical hyperperfusion. The renal vasculopathy also leads to aberrant renal vascular responses to stress that occur systemically or in distant organs and tissues. This response is characterized by enhanced renal vasoconstriction and resultant vasoocclusion. Recurrent cycles of ischaemia and ischaemia–reperfusion injury thus occur, thereby leading to subclinical and clinical acute kidney injury. These processes summate in the initiation and progression of sickle cell nephropathy
  • #18:  https://doi.org/10.1111/j.1365-2141.2011.08853.x
  • #22: Symptoms develop slowly and aren't specific to the disease Can have no symptoms, but people may experience: Whole body: fatigue, high blood pressure, loss of appetite, malaise, or water-electrolyte imbalance Nausea and vomiting, muscle cramps, loss of appetite, swelling via feet and ankles, dry, itchy skin, shortness of breath, trouble sleeping, urinating either too much or too little
  • #24: Urine is an unstable fluid; it changes composition as soon as it is eliminated through micturition.[7] Accurate collection, storage, and handling are crucial to maintaining the sample’s integrity.  A complete urinalysis consists of three components or examinations: physical, chemical, and microscopical.  Preservatives: Although used occasionally, they can alter the accuracy of the results. Some examples include:Thymol: May generate false-positive reactions for albumin. Formaldehyde: May cause false-positive results for leukocyte esterase, peroxidase reaction, urobilinogen, and glucose if strips are used. Hydrochloric Acid: Although used to preserve cell structures and determine steroid concentrations, it affects the sample's pH.  Mercury Salts: May produce false-negative results for leukocyte esterase reaction.  Boric Acid: While commonly used to preserve bacteria present in urine, this substance may reduce the sensitivity of the leukocyte reagent on dipsticks and alter initial pH values. Moreover, excessive concentrations may prevent bacterial growth in samples reserved for culture. roteinuria can my categorized as a glomerular pattern, a tubular pattern, and an overflow pattern  According to the Kidney Disease Improving Global Outcomes (KDIGO) guidelines, albuminuria can be classified into three stages: A1 (less than 30 mg/g creatinine; normal to mildly increased), A2 (30 mg/g to 300 mg/g creatinine; moderately increased, formerly termed as "microalbuminuria"), and A3 (greater than 300 mg/g creatinine; severely increased) Haematuria Dipstick test for blood detects primarily the peroxidase activity of erythrocytes, but myoglobin and hemoglobin can also catalyze this reaction. Thus, a positive test result indicates hematuria, myoglobinuria, or hemoglobinuria.